Todd Waldman
- Oncology top 0.2%
- Cancer-related Molecular Pathways 20
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 7
- Molecular Biology top 0.5%
- PI3K/AKT/mTOR signaling in cancer 15
- Genomics and Chromatin Dynamics 12
- Epigenetics and DNA Methylation 8
- CRISPR and Genetic Engineering 7
- Ubiquitin and proteasome pathways 7
- Biotechnology top 0.2%
- Genetics top 1%
- Glioma Diagnosis and Treatment 10
Todd Waldman
66 papers receiving 10.7k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Oncology 5.7k
- Cancer Research 2.0k
- Molecular Biology 8.0k
- Biotechnology 946
- Genetics 834
Countries citing papers authored by Todd Waldman
This map shows the geographic impact of Todd Waldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Waldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Waldman more than expected).
Fields of papers citing papers by Todd Waldman
This network shows the impact of papers produced by Todd Waldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Waldman. The network helps show where Todd Waldman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Todd Waldman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 12 | |
| 2 | 2021 | 7 | |
| 3 | 2019 | 30 | |
| 4 | 2018 | 24 | |
| 5 | 2017 | 14 | |
| 6 | 2016 | 38 | |
| 7 | 2014 | 48 | |
| 8 | 2014 | 347 | |
| 9 | 2013 | 58 | |
| 10 | 2012 | 52 | |
| 11 | 2011 | 113 | |
| 12 | 2011 | 311 | |
| 13 | 2011 | 19 | |
| 14 | 2010 | 254 | |
| 15 | 2009 | 74 | |
| 16 | 2009 | 26 | |
| 17 | 2008 | 38 | |
| 18 | 2008 | 102 | |
| 19 | Disruption of p53 in human cancer cells alters the responses to therapeutic agentsbreakdown → | 1999 | 883 |
| 20 | 1997 | 329 |
About Todd Waldman
Todd Waldman is a scholar working on Genetics, Oncology and Molecular Biology, having authored 66 papers that have together received 10.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (20 papers), PI3K/AKT/mTOR signaling in cancer (15 papers), Genomics and Chromatin Dynamics (12 papers), Glioma Diagnosis and Treatment (10 papers), Epigenetics and DNA Methylation (8 papers), CRISPR and Genetic Engineering (7 papers), Ubiquitin and proteasome pathways (7 papers) and Cancer Genomics and Diagnostics (7 papers). The work is most often cited by research in Oncology (5.7k citations), Cancer Research (2.0k citations) and Molecular Biology (8.0k citations). Todd Waldman has collaborated with scholars based in United States, United Kingdom and Austria. Frequent co-authors include Bert Vogelstein, Kenneth W. Kinzler, Christoph Lengauer, Fred Bunz, K. W. Kinzler, Jung-Sik Kim, Steven Zhou, John M. Sedivy, Jeremy Brown and Annie Dutriaux. Their work appears in journals such as Cancer Research, Neuro-Oncology, Journal of Biological Chemistry, Molecular and Cellular Biology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.